HOME >> BIOLOGY >> NEWS
Phase II trials of second-generation antisense cancer drug planned following successful early study

Geneva, Switzerland: Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

In the Phase I study the drug OGX-011* inhibited the production of clusterin, a protein that protects cell survival and is widely distributed in body tissue. Clusterin is implicated in a range of activities, including apoptosis (programmed cell death). When it is over-produced, as it is many major cancers, clusterin can stop cancer cells from dying and counters the effectiveness of chemotherapy, hormone treatment and radiotherapy.

Dr. Kim Chi, assistant professor of medicine at the University of British Columbia and medical oncologist at the BC Cancer Agency in Canada, told the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday 29 September) that the Phase I trial was unique in that the clinical research team was able to demonstrate that the target clusterin was inhibited by OGX-011 in patients' cancers in a dose dependent way.

"This means that the drug is doing what it is supposed to be doing something that we can't always say about targeted therapeutics and we were able to identify a biologically active dose," he said.

Antisense drugs work by inhibiting the production of a protein from a specifically targeted gene. As a second-generation antisense drug, OGX-011 is an advance on earlier ones in that the molecules have a longer tissue half life and are potentially more potent. Pre-clinical studies had shown that blocking the production of clusterin with OGX-011 impairs a cancer cell's survival mechanism and enhances the effectiveness of standard chemotherapy, radiation and hormone therapy.

Twenty-five patients with localised prostate cancer that was to be removed by surgery were given escalati
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
29-Sep-2004


Page: 1 2

Related biology news :

1. OneWorld Health completes enrollment, treatment in Phase III India trial
2. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
3. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
4. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
5. KEPPRA international Phase IV SKATE study results show favourable efficacy
6. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
7. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
8. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
9. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
10. Phase transition in bilayers could affect their performance
11. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/7/2019)... ... November 07, 2019 , ... R3 Stem Cell is ... through the rest of 2019. The code to use during checkout is FIFTYOFF and ... R3 is the nation’s leader in regenerative therapies with over 12,000 successful stem cell ...
(Date:11/5/2019)... ... November 05, 2019 , ... Catalent, the leading ... gene therapies, and consumer health products, today announced it will present at the ... on Nov. 12 – 14, 2019. , On Wednesday, Nov. 13 at 3:20 ...
(Date:10/30/2019)... ... October 29, 2019 , ... LGC Maine Standards releases ... Order Numbers 701sa & 704sa. The kits, in a human-urine matrix, evaluate CA, ... Each VALIDATE® kit, liquid, ready-to-use, and prepared using the CLSI EP06-A “equal delta” ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... ... November 12, 2019 , ... ... they have been selected by Lantern Pharma to provided preclinical screening and drug ... millions of data points using panels of unique and genetically edited cell lines ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies , a ... Genedata Biologics® to streamline their R&D operations related to the discovery ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... for the food and beverage industry launched a new innovative website. , After ... experience. Now, the website offers global visitors updated ingredient usage tables by food ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... their new Director of Forensic Genealogy, Melinde Lutz Byrne, to the organization. Byrne’s ... to ultimately provide investigative leads to law enforcement through proven genealogy and DNA ...
Breaking Biology Technology:
Cached News: